As a result, Treg cells in peripheral blood were depleted, but antitumor effector T response was not achieved.132 In contrast, daclizumab followed by vaccination potentiated the antitumor response in breast cancer patients.133 Since Treg cells produce TGFβ, a cytokine whose signaling promotes cancer progression and metastasis of several types of cancers, additional therapeutic efforts are oriented to target TGFβ receptors. This evidence concerns the gene TGFB1 and cancer.